<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2288249</identifier>
<setSpec>0210-4806</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Rioja Sanz, L A</dc:author>
<dc:author>González Enguita, C</dc:author>
<dc:author>Roncalés Badal, A</dc:author>
<dc:author>Gil Sanz, M J</dc:author>
<dc:author>Tello Royloa, C</dc:author>
<dc:author>Martínez Bengoechea, J</dc:author>
<dc:description xml:lang="en">Management of renal cells carcinoma still remains a therapeutic challenge. Nephrectomy is the primary therapy when the disease has a definite location. In advanced or disseminated cases, the various traditional procedures, including radiotherapy, chemotherapy or hormonal regimes, have obtained poor responses. Survival shows a direct relationship with the biological aggressiveness of the tumour and histological factors. Results recorded in the literature using specific immunotherapeutic agents are encouraging although the real value of this regimes has not yet been established in large series of prospective studies. The Oncology Unit of our Urology Service has obtained optimal follow-up in a group of patients included in a combined protocol of interferon alpha-2a and vinblastine as cytotoxic agent.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>1990 Sep-Oct </dc:date>
<dc:title xml:lang="es">Cáncer metastásico de riñón. Experiencia con interferón alpha-2a y vimblastina.</dc:title>
<dc:title xml:lang="en">[Metastasizing kidney cancer. Experience with interferon alfa-2a and vinblastine].</dc:title>
<dc:publisher>Actas urologicas espanolas</dc:publisher>
</metadata>
</record>
</pubmed-document>
